SanofiIt was recently announced that its Tilizumab Injection (trade name: Terico) has been approved by the China National Medical Products Administration (NMPA) for use in children aged 8 years and above and adults with type 1 diabetes stage 2 to delay progression to type 1 diabetes stage 3.
　　Type 1 diabetes is an autoimmune disease caused by the immune system's destruction of pancreatic beta cells, leading to insufficient insulin secretion or even "starvation." Patients require lifelong insulin replacement therapy. my country has approximately 600,000 people with type 1 diabetes, ranking third globally. The disease is most common among children and adolescents aged 10-14 years, with a nearly fourfold increase in incidence over the past 20 years.
　　Clinically, type 1 diabetes progresses insidiously, with patients in stages 1 and 2 exhibiting few typical symptoms of diabetes, such as the "three mores and one less" (excessive eating, drinking, and urination, as well as weight loss). Most patients are diagnosed unexpectedly after being rushed to the hospital for acute and severe illness, with over 60% of children diagnosed in the emergency room or ICU. By this point, the disease has progressed to stage 3, with near-pancreatic failure. Persistent hyperglycemia can cause ketoacidosis (DKA), and in severe cases, can lead to long-term, irreversible damage such as brain damage and kidney failure. Studies have shown that if type 1 diabetes progresses to stage 3 before the age of 10, life expectancy is shortened by 16 years.
　　At the same time, families with type 1 diabetes face a tremendous physical and mental burden. Stage 3 type 1 diabetes patients require at least four insulin injections daily, amounting to over 1,460 injections per year, not including finger pricks for blood sugar monitoring. Maintaining stable blood sugar levels requires extremely disciplined diet and rigorous exercise management.
　　Tilizumab is a CD3-targeted monoclonal antibody that can protect pancreatic islet function at the root cause, delaying the progression of type 1 diabetes from stage 2 to stage 3 by nearly three years. This approval marks another major milestone for the product, following the issuance of the first prescriptions in Asia at the Boao Forum for Asia in June of this year. This approval is driving a breakthrough in the treatment of type 1 diabetes in my country, moving from "passive treatment" to "active intervention," at a world-leading pace.
　　Shi Wan, President of Sanofi Greater China, said: “Thanks to the government’s accelerated development of innovative drugsThanks to our efforts in bringing this product to market, Trinidad and Tobago has achieved full market access in China, moving from pilot trials in Boao to full access in the Chinese market at a world-leading pace. This innovative product is also a key strategic product for Sanofi in the immune-mediated field and in diabetes, where we have a century of expertise. From the large population of type 2 diabetes to the more pressing type 1 diabetes population, Sanofi will continue to deepen collaboration with all sectors of society to promote the improvement of China's type 1 diabetes prevention and treatment system."
　　Professor Weng Jianping, the 7th Chairman of the Diabetes Society of the Chinese Medical Association, stated, "The approval of tislelizumab is of epoch-making significance for the prevention and treatment of type 1 diabetes in my country. Every patient intervened means a family that benefits. This not only provides patients with a valuable 'delay period' for the disease and gives families ample time to prepare both physically and mentally, but also significantly reduces the incidence of potentially life-threatening critical illnesses and alleviates the burden of mid- to long-term treatment and care. For children and adolescents, this secures a 'critical period' for growth and development, as well as the high school entrance exams. For young people, it safeguards a 'golden period' for career development, marriage, and childbearing. This is of great significance in promoting a type 1 diabetes-friendly society."
　　Professor Zhou Zhiguang, Director of the National Clinical Research Center for Metabolic Diseases, emphasized, "Type 1 diabetes carries a genetic risk, and the risk for first-degree relatives can be as high as 15 times that of the general population. Early screening is key, and pancreatic autoantibodies are a decisive indicator for early screening. The newly released "Guidelines for the Prevention and Treatment of Diabetes in China (2024 Edition)" recommends regular early screening for high-risk individuals. Early screening can reduce the risk of ketoacidosis by 90%."
https://finance.eastmoney.com/a/202509063506732767.html